期刊文献+

疾病体外检测和诊断技术的新发展 被引量:2

下载PDF
导出
摘要 从全球范围来看,疾病体外检测、诊断试剂的需求在不断增长,年增长率达到5.5%;我国诊断试剂的市场增长率达到近20%。特异、敏感和快速的疾病体外检测和诊断方法是预防和治疗疾病的重要手段和前提。一些新的检测技术和平台正逐渐应用于疾病的检测和诊断,引起了越来越多的关注。随着纳米技术(nanotechnology)和材料的兴起与蓬勃发展,依赖纳米材料和技术的新的疾病诊断方法的研究正在成为疾病检测和诊断的热点;
出处 《中国医药生物技术》 CSCD 2011年第6期401-404,共4页 Chinese Medicinal Biotechnology
  • 相关文献

参考文献22

  • 12011中国诊断试剂市场趋势观察研究预测报告.[2011-11-24].http://www.chinayearbook.com/report/book_83809.htm.
  • 2Allhoff E Lin P, Moore D. What is nanotechnology and why does it matter: from science to ethics. Hoboken, NJ: John Wiley and Sons,2010:3-5.
  • 3Agrawal A, Tripp RA, Anderson L J, et al. Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. J Virol, 2005, 79(13):8625-8628.
  • 4Wilson R. The use of gold nanoparticles in diagnostics and detection. Chem Soc Rev, 2008, 37(9):2028-2045,.
  • 5Tang S, Hewlett IK. Europium nanoparticle-based immunoassays for sensitive detection of pathogens. Chem Today, 2009, 27(6):50-52.
  • 6Tang S, Zhao J, Storhoff JJ, et al. Nanoparticle-Based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. J Acquit Immune Defic Syndr, 2007, 46(2):231-237.
  • 7Nam JM, Thaxton CS, Mirkin CA. Nanoparficle-based bio-bar codes for the ultrasensitive detection of proteins. Science, 2003, 301(5641): 1884-1886.
  • 8Mason JT, Xu L, Sheng ZM, et al. A liposome-PCR assay for the ultrasensitive detection of biological toxins. Nat Biotechnol, 2006, 24(5):555-557.
  • 9Wang J, Liu G, Jan MR. Ultrasensitive electrical biosensing of proteins and DNA: carbon-nanotube derived amplification of the recognition and transduction events. J Am Chem Soc, 2004, 126(10): 3010-3011.
  • 10Tang S, Moayeri M, Chen Z, et al. Detection of anthrax toxin by an uttrasensitive immunoassay using europium nanoparticles. Clin Vaccine Immunot, 2009, 16(3):408-413.

同被引文献13

  • 1Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP) [J]. Cardiovasc J Afr, 2013, 24:286-289.
  • 2McKie PM, AbouEzzeddine OF, Scott CG, et al. High-sensitivity troponin I and amino-terminal pro-B-type natriuretic peptide predict heart failure and mortality in the general population [ J ]. Clin Chem, 2014, 60:1225-1233.
  • 3Palazzuoli A, Beltrami M, Ruocco G, et al. The role of natriuretic peptides for the diagnosis of left ventricular dysfunction [ J]. ScientificWorldJournal, 2013, 2013:784670.
  • 4FDA (2010), Premarket Notification, 510 (k) for Elecsys proBNP II STAT Assay [ EB/OL ]. [ 2010-03-05 ]. http://www. accessdata, fda. gov/cdrh_docs/pdfg/k092649, pdf.
  • 5IFCC(2012). Maksimiljan Gorenjak, MSc. Natriuretic peptides in assessment of ventricular dysfunction [ EB/OL].http:// www. ifcc. org/ifccfiles/docs/1402062003011, pdf.
  • 6IFCC (2007) . Roberto Latini, Serge Masson. NT-proBNP: A guide to improve the management of patients with heart failure [EB/OL]. http://www, ifcc. org/media/251278/03_Latini. pdf.
  • 7Iwasaki M, Joki N, Tanaka Y, et al. Efficacy of N-terminal pro- brain natriuretic peptide digit number for screening of cardiac disease in new haemodialysis patients[J]. Nephrology (Carlton), 2013, 18:497-504.
  • 8Velibey Y, Golcuk Y, Goleuk B, et al. Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure[J]. 2013, 31:1634-1637.
  • 9Luckenbill KN, Christenson RH, Jaffe AS, et al. Cross- Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays:Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac Damage [ J ]. Clin Chem, 2008, 54:619-621.
  • 10丛玉隆.POCT的临床应用与存在的问题[J].中华检验医学杂志,2007,30(12):1325-1328. 被引量:81

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部